ANNX enters the week with a sharp tension at its core: an analyst just doubled his price target while short sellers have quietly built one of the more substantial short positions in small-cap biotech.
The most striking move this week came from the Street, not the tape. Needham's Joseph Stringer raised his price target on Annexon from $11 to $25 — more than doubling it — while reaffirming his Buy rating, a move filed this morning. That is a rare, high-conviction revision. It comes against a stock trading at $5.55, implying more than 350% upside to the new target. The mean analyst target across the coverage group is $14.88. Goldman Sachs, which initiated in May at Neutral with a $7 target, sits well below the bullish camp — a meaningful split. The bull case centres on ANX005's 10-point MRC sum score improvement over standard-of-care therapies, a result that is genuinely rare in neurology, plus the early completion of Phase 3 enrollment for ANX007 and its entry into the EMA's PRIME PDC pilot. The bear case is more prosaic: a $49.2 million net loss, no revenue, and the usual regulatory uncertainty that shadows pre-commercial biotechs. The 12-month forward EPS momentum factor ranks in the 90th percentile — forward estimates are moving up sharply — but the short score rank sits in just the 13th percentile, a reminder that the positioning community is far less sanguine than the buy-side analysts.
Short interest tells the more uncomfortable story for bulls. At nearly 20% of the free float — up 7.2% over the past week and 17% over the past month — short sellers have been steadily building exposure into the stock's recent strength. ANNX gained 17.8% last month before giving back 13.7% this week, closing Tuesday at $5.55. The short position now stands at roughly 28.9 million shares, with the FINRA fortnightly figure confirming 29.6 million shares short at end-June and 5.4 days to cover. That is a meaningful overhang for a small-cap biotech without a marketed product. Yet the lending market tells a different story entirely: availability is running at 438%, meaning there are more than four shares available to borrow for every one already lent out. That is loose by any standard — the 52-week low availability reading was still above 200% — and cost to borrow is just 0.5%, barely changed on the week. Short sellers are not scrambling for stock. The position is large, but it is not stressed.
Options positioning has tilted decisively toward calls. The put/call ratio has dropped to 0.21, well below its 20-day average of 0.24 and running nearly 1.5 standard deviations light on puts. That is the most call-heavy configuration in several weeks, consistent with speculative positioning around a potential catalyst. The 52-week PCR range runs from 0.10 to 1.43 — today's reading is closer to the bullish extreme than the fearful one. Options traders appear to be leaning into the Needham target raise, not hedging against it.
Institutional ownership adds an important layer of conviction. FMR (Fidelity) added 8.9 million shares in the quarter to June, lifting its stake to 11.9% of shares outstanding. Redmile Group — a specialist healthcare fund — added 4.5 million shares and holds 8.9%. BlackRock added 2.0 million. State Street added 2.4 million. Four of the top six holders were net buyers in the most recent reporting period, and combined they hold more than 35% of the company. That concentration of specialist and index money provides a degree of float stability even as short interest builds. On the insider side, director Muneer Satter purchased $3.3 million worth of shares in late May at $5.41 — a material, high-conviction purchase at prices close to where the stock trades today. The 90-day net insider position is a buyer by 664,000 shares and $3.6 million.
Earnings are scheduled for August 6. The four most recent quarterly prints have produced moves of +10.8%, -0.2%, -4.4%, and -0.2% on the day — a wide distribution anchored by one large upside event in March. The ORTEX short score has eased from 70.2 on July 7 to 67.2 today, a mild softening but still elevated in absolute terms. The next leg of this story turns on whether the clinical data underpinning Needham's aggressive target revision can close the gap with Goldman's far more cautious $7 anchor — and whether August's earnings update shifts that balance.
See the live data behind this article on ORTEX.
Open ANNX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
